ALS-002200
- Generic Name
- ALS-002200
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Chronic Hepatitis CHCVHepatitis CCHC
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 23
- Registration Number
- NCT01842451
- Locations
- 🇳🇿
New Zealand, Christchurch, New Zealand
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01790100
- Locations
- 🇲🇩
Arensia, Republican Clinical Hospital, Chisinau, Moldova, Republic of
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT01726946
- Locations
- 🇺🇸
Florida, Orlando, Florida, United States
🇺🇸Texas, Houston, Texas, United States
🇺🇸Tennessee, Germantown, Tennessee, United States
First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01590407
- Locations
- 🇷🇴
Arensia, Bucharest, Romania
🇫🇷Biotrial, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath